학술논문
SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
Document Type
ConferencePaper
Author
Source
ANNALS OF ONCOLOGY. 32:S1316-S1317
Subject
Language
English
English
English
ISSN
0923-7534